Eyes open to stem cells: safety trial may pave the way for cell therapy to treat retinal disease in patients

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A clinical trial using human embryonic stem cell (hESC) therapy for an inherited retinal degenerative disease is about to commence. The Advanced Cell Technology (ACT) trial will treat patients with Stargardt's macular dystrophy using transplanted retinal pigment epithelium derived from hESCs. Currently, no effective treatment is available for Stargardt's disease so a stem cell-based therapy that can slow progression of this blinding condition could represent a significant breakthrough. While there are some hurdles to clear, the ACT trial is a fine example of translational research that could eventually pave the way for a range of stem cell therapies for the retina and other tissues.
Original languageEnglish
Article number47
Pages (from-to)47-50
Number of pages4
JournalStem Cell Research & Therapy
Volume2
Issue number6
DOIs
Publication statusPublished - 2011

Fingerprint

Retinal Diseases
Cell- and Tissue-Based Therapy
Stem cells
Stem Cells
Safety
Technology
Retinal Pigments
Translational Medical Research
Retinal Pigment Epithelium
Macular Degeneration
Retina
Clinical Trials
Tissue
Human Embryonic Stem Cells
Therapeutics

Cite this

@article{d38b9930c1a34028ba029809b498abda,
title = "Eyes open to stem cells: safety trial may pave the way for cell therapy to treat retinal disease in patients",
abstract = "A clinical trial using human embryonic stem cell (hESC) therapy for an inherited retinal degenerative disease is about to commence. The Advanced Cell Technology (ACT) trial will treat patients with Stargardt's macular dystrophy using transplanted retinal pigment epithelium derived from hESCs. Currently, no effective treatment is available for Stargardt's disease so a stem cell-based therapy that can slow progression of this blinding condition could represent a significant breakthrough. While there are some hurdles to clear, the ACT trial is a fine example of translational research that could eventually pave the way for a range of stem cell therapies for the retina and other tissues.",
author = "Medina, {Reinhold J} and Archer, {Desmond B} and Stitt, {Alan W}",
year = "2011",
doi = "10.1186/scrt88",
language = "English",
volume = "2",
pages = "47--50",
journal = "Stem Cell Research & Therapy",
issn = "1757-6512",
publisher = "BioMed Central",
number = "6",

}

TY - JOUR

T1 - Eyes open to stem cells: safety trial may pave the way for cell therapy to treat retinal disease in patients

AU - Medina, Reinhold J

AU - Archer, Desmond B

AU - Stitt, Alan W

PY - 2011

Y1 - 2011

N2 - A clinical trial using human embryonic stem cell (hESC) therapy for an inherited retinal degenerative disease is about to commence. The Advanced Cell Technology (ACT) trial will treat patients with Stargardt's macular dystrophy using transplanted retinal pigment epithelium derived from hESCs. Currently, no effective treatment is available for Stargardt's disease so a stem cell-based therapy that can slow progression of this blinding condition could represent a significant breakthrough. While there are some hurdles to clear, the ACT trial is a fine example of translational research that could eventually pave the way for a range of stem cell therapies for the retina and other tissues.

AB - A clinical trial using human embryonic stem cell (hESC) therapy for an inherited retinal degenerative disease is about to commence. The Advanced Cell Technology (ACT) trial will treat patients with Stargardt's macular dystrophy using transplanted retinal pigment epithelium derived from hESCs. Currently, no effective treatment is available for Stargardt's disease so a stem cell-based therapy that can slow progression of this blinding condition could represent a significant breakthrough. While there are some hurdles to clear, the ACT trial is a fine example of translational research that could eventually pave the way for a range of stem cell therapies for the retina and other tissues.

U2 - 10.1186/scrt88

DO - 10.1186/scrt88

M3 - Article

C2 - 22152341

VL - 2

SP - 47

EP - 50

JO - Stem Cell Research & Therapy

JF - Stem Cell Research & Therapy

SN - 1757-6512

IS - 6

M1 - 47

ER -